75N93023C00055

TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.

National Institutes of Health · United States

This contract has been awarded. Browse open opportunities

View Source

Time Left to Bid

Awarded

AwardedHealthcare & MedicalFederal

Basic information

Reference number: 75N93023C00055
Issuing organization: National Institutes of Health · Find award history →
Government level: Federal
Solicitation type: Healthcare & Medical
Title: TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
Source: USASpending (Federal)
Source ID: usa-75N93023C00055

Details

Location: United States

Description

TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1. Awarded to: ABVIRO LLC Agency: Department of Health and Human Services Sub-agency: National Institutes of Health Award type: DEFINITIVE CONTRACT

Dates

Publication: 2023/09/25 12:00:00 AM UTC
Closing date: 2026/12/31 12:00:00 AM UTC

Estimated value

$11.3M USD

Classification

Normalized category

Healthcare & Medical

Source: USASpending (Federal)

Last updated 2026-05-25, 2:38:01 p.m.

Data refreshed every 2 hours